Supplementary-Table-6. Treatment modalities and reported adverse events by quartile of period of inclusion. *NA*: not applicable

	Overall	Quartile 1	Quartile 2	Quartile 3	Quartile 4	p-value (Quartiles)
	n/N (%), or median [interquartile range]					
Treatments						
Corticosteroids	36/40 (90%)	10/10 (100%)	9/10 (90%)	8/10 (80%)	9/10 (90%)	0.35
- days from presentation to start	1 [0; 3]	2 [0; 4]	1 [0; 2]	1 [0; 6]	1 [0; 3]	0.87
- days from severe criteria to start	-3 [-3; 0]	0 [-6; 1]	-1 [-3; 1]	-3 [-5; -2]	-3 [-4; 0]	0.42
- maximal dose (g/day)*	0.9 [0.05; 1]	1 [1; 1]	1 [1; 1]	0.05 [0.02; 0.3]	0.06 [0.03; 0.6]	0.0005
- mean dose in 1st month (mg/day)*	117 [40;165]	155 [123; 223]	165 [114; 190]	42 [0; 101]	53 [16; 131]	0.005
Abatacept	29/40 (73%)	7/10 (70%)	8/10 (80%)	6/10 (60%)	8/10 (80%)	0.87
- days from presentation to start	6 [2; 13]	7 [2; 17]	4 [1; 16]	5 [2; 10]	7 [4; 15]	0.75
- days from severe criteria to start	2 [1; 4]	3 [2; 9]	2 [0; 12]	1 [1; 2]	3 [1; 4]	0.54
- total number of doses	5 [3; 6]	3 [2; 8]	6 [5; 8]	4 [4; 5]	5 [3; 5]	0.05
- mean dosage /administration (mg/kg)	19 [16; 21]	17 [12; 20]	18 [16; 20]	21 [18; 23]	20 [16; 21]	0.15
- total dose within 15days of start (mg/kg)	60 [45; 63]	41 [24; 60]	59 [54; 70]	63 [59; 71]	59 [39; 64]	0.05
Ruxolitinib	18/40 (45%)	0/10 (0%)	6/10 (60%)	5/10 (50%)	7/10 (70%)	0.005
- days from presentation to start	8 [3; 12]	NA	8 [2; 30]	5 [2; 22]	8 [4; 17]	0.96
- days from severe criteria to start	3 [1; 7]	NA	5 [1; 46]	1 [0; 11]	3 [1; 6]	0.81
- maximal dose (mg/day)	30 [30; 30]	NA	30 [30; 30]	30 [20; 30]	30 [30; 30]	0.28
- mean dose (mg/day)	27 [24; 29]	NA	28 [26; 28]	21 [12; 24]	22 [19; 24]	0.0009
- duration of treatment (days)	24 [15; 36]	NA	28 [20; 43]	20 [18; 33]	25 [9; 39]	0.71
Intravenous immunoglobulin**	7/40 (18%)	2/10 (20%)	2/10 (20%)	0/10 (0%)	3/10 (30%)	0.85
Plasmapheresis	10/40 (25%)	8/10 (80%)	2/10 (20%)	0/10 (0%)	0/10 (0%)	<0.0001
Mycophenolate mofetil	6/40 (15%)	4/10 (40%)	1/10 (10%)	0/10 (0%)	1/10 (10%)	0.05
Tacrolimus	1/40 (2%)	1/10 (10%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0.17
Adverse events ***						
Infections (non COVID-19)	18/40 (45%)	6/10 (60%)	5/10 (50%)	3/10 (30%)	4/10 (40%)	0.25
- fatal	2/40 (5%)	2/10 (20%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0.05
COVID-19	6/40 (15%)	0/10 (0%)	2/10 (20%)	4/10 (40%)	0/10 (0%)	0.69
- fatal	3/40 (8%)	0/10 (0%)	1/10 (10%)	2/10 (20%)	0/10 (0%)	0.79
Venous thrombo-embolism	7/40 (18%)	4/10 (40%)	3/10 (30%)	0/10 (0%)	0/10 (0%)	0.005
Hemorrhage exteriorized	3/40 (8%)	1/10 (10%)	0/10 (0%)	1/10 (10%)	1/10 (10%)	0.79
Anemia requiring transfusion	12/40 (30%)	4/10 (40%)	5/10 (50%)	1/10 (10%)	2/10 (20%)	0.12
Diabetes (cortico-induced)	7/36 (19%)	3/10 (30%)	2/9 (22%)	2/8 (25%)	0/9 (0%)	0.13

** dose equivalent to intravenous methylprednisolone in milligram (mg) per day in all patients*

*** Intravenous immunoglobulin started by other teams before transfer to our hospital for poor evolution and stopped upon admission in our hospital in 5/7 cases*

**** evaluated during the index hospitalization for myotoxicity, or active treatment with immunossupressant (i.e, prednisone per os≥7mg/day), whichever period of follow-up is longer*